Cube Pharmaceuticals announced that the company participated in the centralized drug procurement declaration organized by the state, and that doxazosin mesylate extended-release tablets and mesartan potassium tablets will be selected. In 2025, sales revenue of doxazosin mesylate extended-release tablets was RMB 103.4095 million, accounting for 6.66% of that year's revenue; mesartan potassium tablets were approved for listing on May 19, 2026, and no revenue was generated. The procurement period starts from the execution of the selection results to December 31, 2029. If a procurement contract is subsequently signed and implemented, it will have a positive impact on the company's performance. However, the proposed election results still need to be publicized and confirmed, and there is uncertainty about the next steps.

Cube Pharmaceuticals announced that the company participated in the centralized drug procurement declaration organized by the state, and that doxazosin mesylate extended-release tablets and mesartan potassium tablets will be selected. In 2025, sales revenue of doxazosin mesylate extended-release tablets was RMB 103.4095 million, accounting for 6.66% of that year's revenue; mesartan potassium tablets were approved for listing on May 19, 2026, and no revenue was generated. The procurement period starts from the execution of the selection results to December 31, 2029. If a procurement contract is subsequently signed and implemented, it will have a positive impact on the company's performance. However, the proposed election results still need to be publicized and confirmed, and there is uncertainty about the next steps.